248 related articles for article (PubMed ID: 12119297)
21. Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis.
Holtz B; Cuniasse P; Boulay A; Kannan R; Mucha A; Beau F; Basset P; Dive V
Biochemistry; 1999 Sep; 38(37):12174-9. PubMed ID: 10508422
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
23. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
25. Fluorescent oligopeptide substrates for kinetic characterization of the specificity of Astacus protease.
Stöcker W; Ng M; Auld DS
Biochemistry; 1990 Nov; 29(45):10418-25. PubMed ID: 2261483
[TBL] [Abstract][Full Text] [Related]
26. In vitro cleavage of internally quenched fluorogenic human proparathyroid hormone and proparathyroid-related peptide substrates by furin. Generation of a potent inhibitor.
Lazure C; Gauthier D; Jean F; Boudreault A; Seidah NG; Bennett HP; Hendy GN
J Biol Chem; 1998 Apr; 273(15):8572-80. PubMed ID: 9535830
[TBL] [Abstract][Full Text] [Related]
27. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase.
Verheijen JH; Nieuwenbroek NM; Beekman B; Hanemaaijer R; Verspaget HW; Ronday HK; Bakker AH
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):603-9. PubMed ID: 9169591
[TBL] [Abstract][Full Text] [Related]
28. Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site.
Fields GB; Van Wart HE; Birkedal-Hansen H
J Biol Chem; 1987 May; 262(13):6221-6. PubMed ID: 3032960
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
30. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain.
Wang Y; Johnson AR; Ye QZ; Dyer RD
J Biol Chem; 1999 Nov; 274(46):33043-9. PubMed ID: 10551873
[TBL] [Abstract][Full Text] [Related]
31. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.
Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; Bannow C; Reardon IM; Howe WJ; DeCamp DL; Craik CS; Heinrikson RL
J Biol Chem; 1990 Aug; 265(24):14675-83. PubMed ID: 2201691
[TBL] [Abstract][Full Text] [Related]
32. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
33. The roles of substrate thermal stability and P2 and P1' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity.
Minond D; Lauer-Fields JL; Cudic M; Overall CM; Pei D; Brew K; Visse R; Nagase H; Fields GB
J Biol Chem; 2006 Dec; 281(50):38302-13. PubMed ID: 17065155
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.
Okada Y; Morodomi T; Enghild JJ; Suzuki K; Yasui A; Nakanishi I; Salvesen G; Nagase H
Eur J Biochem; 1990 Dec; 194(3):721-30. PubMed ID: 2269296
[TBL] [Abstract][Full Text] [Related]
35. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases.
Tözsér J; Weber IT; Gustchina A; Bláha I; Copeland TD; Louis JM; Oroszlan S
Biochemistry; 1992 May; 31(20):4793-800. PubMed ID: 1591240
[TBL] [Abstract][Full Text] [Related]
36. High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues.
Szabó A; Héja D; Szakács D; Zboray K; Kékesi KA; Radisky ES; Sahin-Tóth M; Pál G
J Biol Chem; 2011 Jun; 286(25):22535-45. PubMed ID: 21515688
[TBL] [Abstract][Full Text] [Related]
37. The cell envelope-bound metalloprotease (camelysin) from Bacillus cereus is a possible pathogenic factor.
Fricke B; Drössler K; Willhardt I; Schierhorn A; Menge S; Rücknagel P
Biochim Biophys Acta; 2001 Sep; 1537(2):132-46. PubMed ID: 11566257
[TBL] [Abstract][Full Text] [Related]
38. Degradation of tropoelastin by matrix metalloproteinases--cleavage site specificities and release of matrikines.
Heinz A; Jung MC; Duca L; Sippl W; Taddese S; Ihling C; Rusciani A; Jahreis G; Weiss AS; Neubert RH; Schmelzer CE
FEBS J; 2010 Apr; 277(8):1939-56. PubMed ID: 20345904
[TBL] [Abstract][Full Text] [Related]
39. Complete amino acid sequence of copper-zinc superoxide dismutase from Drosophila melanogaster.
Lee YM; Friedman DJ; Ayala FJ
Arch Biochem Biophys; 1985 Sep; 241(2):577-89. PubMed ID: 3929689
[TBL] [Abstract][Full Text] [Related]
40. ADAM33 enzyme properties and substrate specificity.
Zou J; Zhang R; Zhu F; Liu J; Madison V; Umland SP
Biochemistry; 2005 Mar; 44(11):4247-56. PubMed ID: 15766253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
